Bayer Schering, Epix to end Vasovist partnership

Contrast agent firms Bayer Schering Pharma and Epix Pharmaceuticals have agreed to end their marketing partnership for the Vasovist blood-pool MR angiography agent that Epix developed, the Lexington, MA-based firm said.

Bayer Schering Pharma of Berlin will transfer Vasovist rights to Epix by December 31 of this year; the collaboration agreement between the two companies will end March 1, 2009. Until that time, Bayer Schering Pharma will continue to provide Vasovist to the 19 countries where the agent is currently marketed.

Related Reading

Epix to form technology advisory board, August 14, 2008

Epix's Q2 results show boosted revenues, August 7, 2008

Epix secures equity financing, August 5, 2008

Epix CEO resigns, July 28, 2008

Epix wins South Korean approval of Vasovist, July 10, 2008

Copyright Β© 2008

Page 1 of 179
Next Page